Joan Adam, Secretary of Health

South Dakota Department of Health Logo and button.

COVID-19 Vaccine Information

for healthcare providers

NOTE: Please check this web page twice weekly for updated material.

Provider Enrollment Instructions

Vaccinator TrainingStorage & Handling TrainingVaccine Data Entry Training Vaccine Coordinator Training


Updates for Vaccine Providers

Booster Dose for Children ages 5-11 years

On Friday,05/20/2022, the CDC endorsed the Advisory Committee on Immunization Practices (ACIP)’s vote to expand eligibility and update recommendations for COVID-19 booster doses.

All children ages 5 through 11 years should now receive a booster vaccine 5 months after completing their primary series. Children ages 5 through 11 years who are moderately or severely immunocompromised should receive a booster 3 months after completing their primary series. CDC continues to recommend a booster for children and adolescents ages 12 through 17. Only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for children 5 through 17 years old. Parents with questions are encouraged to talk to their child’s healthcare provider, school nurse, or local pharmacist to learn more about the booster, and the importance of keeping children up to date with COVID-19 as well as other childhood vaccines. 

In addition, CDC strengthened its COVID-19 vaccination guidance to recommend that everyone ages 50 years and older who received any COVID-19 booster dose—as well as everyone ages 12 years and older who are moderately or severely immunocompromised—receive a second booster dose using an mRNA COVID-19 vaccine. Previously, CDC had encouraged these populations to consider receiving a second booster dose based on their individual circumstances. However, over the past few weeks, we have seen a steep and substantial increase in hospitalizations for older Americans. Another COVID-19 booster dose could help restore protection that may wane over time.

Vaccine Inventory Reminders

Cartons and vials of Pfizer-BioNTech COVID-19 PURPLE Cap vaccine with labeled expiration dates of October 2021 through November 2022 may now be used beyond the printed date. The new updated expiry dates can be found HERE. These vaccines may remain in use until the updated expiration date providing approved storage conditions have been maintained.

We appreciate your efforts to reduce the Pfizer PURPLE Cap vaccine inventory in the field, which continues to decline. Please continue to use Pfizer PURPLE Cap before ordering the Pfizer Tris GRAY Cap. Remember to keep your inventory of the purple and gray cap vials separate to avoid any confusion. Purple cap vials require diluent while gray cap vials do not.

Memorial Day Holiday Ordering and Shipping Schedule

In anticipation of the Memorial Day holiday, we urge you to plan on ordering vaccine early. The information provided below clarifies the days on which vaccine will be delivered over the holiday weekend.

  • Pfizer-BioNTech Vaccines

    • No vaccine deliveries will occur on Monday, May 30 (Memorial Day).

    • If you need vaccine for clinics over the weekend, you may submit orders earlier in the week before the holiday (Monday 5/23 or Tuesday 5/24).

  • Moderna and J&J/Janssen Centrally Distributed Vaccines

    • No vaccine deliveries will occur on Monday, May 30, or Tuesday, May 31 (you may receive ancillary kits on Tuesday for orders arriving on June 1).

Updated Storage & Handling Toolkit

The Vaccine Storage and Handling Toolkit has been updated with a COVID-19 Vaccine Addendum with information on Storage and Handling best practices for COVID-19 vaccines. All vaccination providers participating in the COVID-19 Vaccination Program must store and handle COVID-19 vaccines under proper conditions to maintain the cold chain as outlined in the toolkit and addendum. This addendum will be updated with specific storage and handling information for each COVID-19 product.

For more information about COVID-19 vaccination provider requirements and resources on enrollment, ordering, and data in support of vaccination visit COVID-19 Vaccination Provider Requirements and Support | CDC

Long COVID or Post-COVID Conditions updates

On May 5th, CDC updated the Long COVID or Post-COVID Conditions web page, which provides an overview of what is known about including risks, symptoms, and prevention. CDC also published a new web page, Post-COVID Conditions: CDC Science, to better inform audiences about what CDC and other researchers are doing to answer key questions about post-COVID conditions.

Vaccine Finder Update: Weekly Reporting beginning May 1

UPDATE: As of May 1, 2022, providers must report COVID-19 vaccine supply levels at least weekly by close of business on Fridays. All other provisions regarding data remain unchanged.

Guides for reporting inventory and public display information can be found on the Provider Resources page. If you need support, please contact or 1-833-748-1979.

Adult Ancillary Kit Opt-out

  • J&J opt-out is available

  • Moderna opt-out is available

  • Pfizer ADULT opt-out is now available

If you wish to not receive ancillary kits, please indicate this in the notes section of the order screen in SDIIS.

HRSA Uninsured Administration Reimbursement Ceased on April 5 at 11:59 PM

Further FAQ’s about the claims submission deadlines are online at:

Updated information:

Pfizer-BioNTech COVID-19 Vaccine

Pfizer-BioNTech Resources:

Clinical Materials for Ages 5 through 11 years:

COVID-19 Vaccine Medical Updates and Immunization Site Training

  • Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccine


    • Section 1: Medical Updates & New Information for the Vaccine

      • FDA approvals, authorizations - including recent authorizations

      • CDC Interim Clinical Considerations - recent updates

      • Introduction of new Controlant Temperature Monitoring Device

      • Healthcare provider resources

      • Question and answer session

    • Section 2: Storage, Handling, and Administration of Vaccines

      • Use of each vaccine presentation, including storage, handling, preparation, and administration for:

        • Ages 5 through 11 Years: DILUTE BEFORE USE/Orange Cap

        • Ages 12 Years and Older: DO NOT DILUTE/Gray Cap; DILUTE BEFORE USE/Purple Cap

    • Question and answer session

  • These sessions will be updated to reflect the latest information and recent changes which will be identified at the start of each session.

Contact Information:

Moderna COVID-19 Vaccine Janssen COVID-19 Vaccine

Janssen Website

Shelf Life Extension for the Johnson & Johnson's Janssen COVID-19 Vaccine

The Food & Drug Administration announced the approval of a shelf life extension for the Johnson & Johnson's Janssen COVID-19 vaccine for an additional three months. The shelf life of this vaccine has been updated from 6 months to 9 months. This decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 9 months when refrigerated at temperatures of 36° – 46° Fahrenheit (2°– 8° Celsius).

This shelf life extension applies to all inventory dated to expire on March 7, 2022 or later. Vaccine dated prior to March 7, 2022 should be disposed of according to state and local regulation and reported as waste according to your COVID-19 provider agreement. Vaccine providers should visit the Janssen COVID-19 Vaccine Expiry Checker webpage to confirm the expiration dates. This shelf life extension applies to refrigerated vials of J&J/Janssen COVID-19 vaccine that have been held in accordance with the manufacturer's storage conditions.

COVID-19 vaccines that are authorized under an EUA do not have fixed expiration dates, and expiration dates may be extended as we get more stability data. Always check the manufacturer's website to obtain the most up-to-date expiration dates for the COVID-19 vaccines you have on hand.

Janssen Resources:

Contact Information:

VaccineFinder (VF)


Contact Information:

VAERS - Vaccine Adverse Event Reporting System

VAERS Website - Healthcare providers are required by law to report to VAERS

Contact VAERS at:

  • Phone: 800-822-7967 | Fax: 877-721-0366 | E-mail:   

  • For non-urgent concerns, email For emergencies relating to COVID-19 vaccine safety, call CDC Emergency Operations Center at (770) 488-7100.


v-safe website - CDC is requesting that healthcare providers give patients a v-safe information sheet at the time of vaccination and encourage them to enroll and fill out the surveys when prompted to do so.

Contact Information: Call 800-232-4636 | TTY 888-232-6348 | Open 24 hours, 7 days a week

General Vaccine Guidance and Resources

Pregnancy & Breastfeeding Vaccination Guidance

Pediatric Vaccination Guidance

Vaccination Clinic Guidance

Long-Term Care Facility Guidance

Storage and Handling Guidance

Post-Vaccination Guidance

Fact Sheets & Communication Resources

South Dakota Vaccination Plan

Share via: